Detection of SNCA and FBN1 Methylation in the Stool As a Biomarker for Colorectal Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2015 Mar 25

PMID 25802477

Citations 31

Authors

Wen-Han Li

Hao Zhang

Qi Guo

Xuan-di Wu

Zi-sen Xu

Cheng-Xue Dang

Peng Xia

Yong-Chun Song

Affiliations

Soon will be listed here.

Abstract

Aim: We examined the methylation status of SNCA and FBN1 genes in patients' paired tissue and stool samples for detection of colorectal cancer (CRC).

Patients And Methods: 89 DNA tissue samples (normal/cancer) and corresponding stool samples were analyzed in our study. In addition, 30 stool samples were collected as healthy controls.

Results: The methylation level of those samples was measured by methylation-specific polymerase chain reaction (MSP). The result shows that compared with the paired controls, both SNCA and FBN1 were significantly hypermethylated in CRC patients in tissue samples (P < 0.001). In the stool samples, hypermethylated SNCA and FBN1 were detected to be significantly higher than that in normal stool samples (P < 0.001). The combined sensitivity of at least one positive among the two markers in stool samples was 84.3%, with a specificity of 93.3%. In addition, our experiment suggested that the positive rates of SNCA and FBN1 in Dukes A stage were significantly higher than that of FOBT (P = 0.039; P = 0.006, resp.).

Conclusion: We concluded that methylation testing of SNCA and FBN1 genes in stool sample may offer a good alternative in a simple, promising, and noninvasive detection of colorectal cancer.

Citing Articles

Extensive methylation analysis of circulating tumor DNA in plasma of patients with gastric cancer.

Nagano S, Kurokawa Y, Hagi T, Yoshioka R, Takahashi T, Saito T Sci Rep. 2024; 14(1):30739.

PMID: 39730450 PMC: 11680901. DOI: 10.1038/s41598-024-79252-y.

DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine.

Ye J, Zhang J, Ding W Explor Target Antitumor Ther. 2024; 5(1):34-53.

PMID: 38464391 PMC: 10918240. DOI: 10.37349/etat.2024.00203.

Integrated DNA methylation analysis reveals a potential role for PTPRN2 in Marfan syndrome scoliosis.

Zheng Z, Xu J, Chen J, Jiang B, Ma H, Li L JOR Spine. 2024; 7(1):e1304.

PMID: 38304329 PMC: 10831201. DOI: 10.1002/jsp2.1304.

Alpha-Synuclein in Peripheral Tissues as a Possible Marker for Neurological Diseases and Other Medical Conditions.

Jimenez-Jimenez F, Alonso-Navarro H, Garcia-Martin E, Santos-Garcia D, Martinez-Valbuena I, Agundez J Biomolecules. 2023; 13(8).

PMID: 37627328 PMC: 10452242. DOI: 10.3390/biom13081263.

The Hyperproliferation Mechanism of Cholesteatoma Based on Proteomics: SNCA Promotes Autophagy-Mediated Cell Proliferation Through the PI3K/AKT/CyclinD1 Signaling Pathway.

Gao M, Xiao H, Liang Y, Cai H, Guo X, Lin J Mol Cell Proteomics. 2023; 22(9):100628.

PMID: 37532176 PMC: 10495652. DOI: 10.1016/j.mcpro.2023.100628.

References

Bosch L, Mongera S, Terhaar Sive Droste J, Oort F, van Turenhout S, Penning M . Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection. Cell Oncol (Dordr). 2012; 35(4):309-15. DOI: 10.1007/s13402-012-0092-6. View

Schoen R, Pinsky P, Weissfeld J, Yokochi L, Church T, Laiyemo A . Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366(25):2345-57. PMC: 3641846. DOI: 10.1056/NEJMoa1114635. View

Zhang H, Song Y, Dang C . Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 2013; 10(3):230-4. PMC: 3558710. DOI: 10.7150/ijms.5278. View

Guo Q, Song Y, Zhang H, Wu X, Xia P, Dang C . Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients. Med Oncol. 2013; 30(4):695. DOI: 10.1007/s12032-013-0695-4. View

Schwabe R, Jobin C . The microbiome and cancer. Nat Rev Cancer. 2013; 13(11):800-12. PMC: 3986062. DOI: 10.1038/nrc3610. View

Wu X, Song Y, Cao P, Zhang H, Guo Q, Yan R . Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer. Med Oncol. 2014; 31(4):894. DOI: 10.1007/s12032-014-0894-7. View

Wang X, Kuang Y, Hu X . Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol. 2014; 20(15):4276-87. PMC: 3989963. DOI: 10.3748/wjg.v20.i15.4276. View

Grady W, Rajput A, Lutterbaugh J, Markowitz S . Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 2001; 61(3):900-2. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

10.

Baylin S . Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol. 2002; 12(5):331-7. DOI: 10.1016/s1044-579x(02)00053-6. View

11.

Laird P . The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3(4):253-66. DOI: 10.1038/nrc1045. View

12.

Lengauer C . Cancer. An unstable liaison. Science. 2003; 300(5618):442-3. DOI: 10.1126/science.1084468. View

13.

Belshaw N, Elliott G, Williams E, Bradburn D, Mills S, Mathers J . Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(9):1495-501. View

14.

Leung W, To K, Man E, Chan M, Bai A, Hui A . Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem. 2004; 50(11):2179-82. DOI: 10.1373/clinchem.2004.039305. View

15.

ALLISON J, Tekawa I, Ransom L, Adrain A . A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996; 334(3):155-9. DOI: 10.1056/NEJM199601183340304. View

16.

Castiglione G, Zappa M, Grazzini G, Mazzotta A, Biagini M, Salvadori P . Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer. 1996; 74(1):141-4. PMC: 2074614. DOI: 10.1038/bjc.1996.329. View

17.

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

18.

Lenhard K, Bommer G, Asutay S, Schauer R, Brabletz T, Goke B . Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol. 2005; 3(2):142-9. DOI: 10.1016/s1542-3565(04)00624-x. View

19.

Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington M . Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005; 11(3):1203-9. View

20.

Chen W, Han Z, Skoletsky J, Olson J, Sah J, Myeroff L . Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005; 97(15):1124-32. DOI: 10.1093/jnci/dji204. View